To help break down complex ideas relevant to biotech, we offer periodic, interactive, webinar-style discussions led by members of our team. Each episode begins with an in-depth analysis of recent Covid-19 data. We welcome all those involved in biotechnology or public health, including scientific innovators, policymakers, members of the media, academics, medical professionals, and representatives of non-profits or NGOs.

Previously Recorded Episodes:

November 3, 2021
This month we highlight how the FDA models risk of myocarditis in relatively small trials, the calculus of vaccinating kids for their own sake versus for the sake of herd immunity, and how kids will tolerate the shot. Then Peter Kolchinsky is joined by Josh Cohen of Tufts Medical Center and co-author of The Right Price: A Value Based Prescription for Drug Costs to discuss how we value drugs.
Watch Video

Covid-19 Discussion

October 6, 2021
This month’s RA TV featured Covid vaccines and therapeutics updates as well as an overview of RA Capital’s TechAtlas research division, highlighted by day-in-the-life perspectives from TA Associates. This includes company meetings and analysis, scientific conference preparation and attendance, and opportunities for Associates to grow into roles in venture, equity, or management.
Watch Video

September 8, 2021
Has 2021 been a good year or a bad year for biotech? We highlighted key differences between the XBI and IBB, and dug into the data to understand the recent divergence between large cap and mid cap companies. We ended with a discussion about the latest data on vaccine durability and the need for boosting.
Watch Video

August 4, 2021
In this month’s episode of RA TV, we’ll be joined by a panel from No Patient Left Behind who will discuss ongoing debates on Capitol Hill around healthcare. That discussion will be bookended with a quick download on Biogen’s first-in-class Alzheimer’s drug, Aduhelm, and an update on COVID-19. No Patient Left Behind is a non-profit organization who's mission is to make medicines affordable for everyone in America. More information can be found on their website.
Watch Video

July 7, 2021
Our thoughts on the emerging Delta variant, discussion on recent Ph3 data from Novavax and CureVac, review of the potential association between the mRNA vaccines and risk of myocarditis, analysis of published Ph2 virology data for Merck’s molnupiravir.
Watch Video

June 2, 2021
Update on molnupiravir and sotrovimab/VIR-7831, discussion on the natural vs. lab origin hypotheses of SARS-CoV-2 and implications, and coverage of the evolving vaccine boosting landscape.
Watch Video

May 5, 2021
Discussion on long COVID and the importance of avoiding even mild COVID. Additional vaccine efficacy data from Bharat Biotech, and vaccine safety data in pregnant women. Finally, a brief update on Gilead’s remdesivir and Regeneron’s antibody cocktail.
Watch Video

April 7, 2021
Discussion on Vir’s antibody data in the hospitalized and outpatient settings, and the big picture implications of the antibody therapies for COVID. Overview of how we are thinking about the vaccine booster market and how waning neutralizing antibody titers over time may impact durability, and updates on Pfizer, Moderna and AstraZeneca’s vaccines.
Watch Video

March 3, 2021
Update on the various strategies vaccine developers are pursuing to combat the threat of the new variants. Discussion on recent FDA meeting and EUA for JNJ vaccine. Overview of recent data from a large trial testing the efficacy of colchicine in the outpatient setting.
Watch Video

February 3, 2021
Deep dive into how the new vaccine efficacy data from Novavax and JNJ compare to existing data from Moderna, Pfizer/BioNTech and AstraZeneca. We discussed why we believe Novavax’s platform is best positioned to develop boosters and new vaccines against the different strains.
Watch Video

January 6, 2021
Progress on the US vaccine rollout: is one dose good enough? Can we mix and match vaccines? Allergic reactions associated with mRNA vaccines, and the implications of novel SARS-CoV2 variants.
Watch Video

December 16, 2020
Discussion on at-home covid testing and the first OTC covid diagnostic, Pfizer/BioNTech & Moderna vaccine updates and a vaccine delay from Sanofi/GSK’s program.
Watch Video

December 2, 2020
AstraZeneca vaccine data, baricitinib in combo with remdesivir gets EUA, CD24Fc gets acquired by big pharma and combining AAV gene therapy with covid antibodies for prevention.
Watch Video

November 18, 2020
Positive interim data in Moderna’s Ph3 vaccine trial, how antibody titers diminish over time, aspirin being tested in a large Ph3 randomized control trial in hospitalized patients, Ilaris (an anti-IL-1b monoclonal antibody) fails in a late stage study, FDA approves an “at home” COVID-19 test.
Watch Video

November 11, 2020
Positive interim data from Pfizer/BioNTech’s Ph3 vaccine trial showed >90% efficacy, the risk of novel SARS-CoV2 variants, and update on the EUA for Lilly’s antibody.
Watch Video

November 4, 2020
Regeneron antibody cocktail clinical update, case study on how Taiwan has gone 200 days without a new local infection, FDA panel presents data that some COVID-19 tests are not very good, poll of Americans regarding vaccine hesitancy, monitoring vaccine safety after approval.
Watch Video

October 27, 2020
Discussion on the Remdesivir approval, Vaccines Adcom, and risk of COVID-19 transmission on airplanes.
Watch Video

October 21, 2020
Discussion of results from the WHO’s trial of Remdesivir and tips on using diagnostics to help plan holiday get-togethers.
Watch Video

October 14, 2020
Exploration of why people are still getting sick with infectious diseases despite self-isolating, details on the J&J vaccine trial hold, and a discussion of the FDA’s vaccine EUA guidelines.
Watch Video

October 7, 2020
Discussion of the newly released data for Regeneron’s mAb cocktail and also on how the White House is dealing with a COVID-19 outbreak.
Watch Video

September 29, 2020
Case studies of how diagnostics can help reduce the spread of COVID-19 and contextualizing the recent J&J vaccine data.
Watch Video

September 22, 2020
Covid Tx map update, a case for multiplexed trials, and home testing.
Watch Video

September 16, 2020
Discussion of when a COVID-19 vaccine could become available and how much it might cost.
Watch Video

September 10, 2020
Comparing tolerability for vaccine candidates; possibilities of a combined flu/COVID vaccine.
Watch Video

September 1, 2020
Emergency use authorization and how it may impact vaccine development; Follow up on human convalescent serum and the broadening of Remdesivir’s label; Approval of Abbot’s diagnostic test; Concerns around herd immunity and evaluating Sweden’s approach.
Watch Video

August 26, 2020
What data did human convalescent serum show for approval, and what does this mean for companies developing antibodies; What would accelerated approval for a vaccine mean for opening up the country, and the development of other vaccines; Possibilities of reinfection.
Watch Video

August, 19 2020
Walkthrough of comparative vaccine data for the major vaccines in development; Discussion of immune modulators as COVID therapy.
Watch Video

August 12, 2020
Walkthroughs by the RA team on COVID Vaccines, Therapeutics, and Diagnostics, highlighting the most interesting programs in development.
Watch Video